Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Radiology, Nuclear Medicine & Medical Imaging, Brain, Dopamine, D2 receptor, SPECT, PET, Parkinsonism, MULTIPLE SYSTEM ATROPHY, POSITRON-EMISSION-TOMOGRAPHY, PARKINSONS-DISEASE, DIFFERENTIAL-DIAGNOSIS, HUNTINGTONS-DISEASE, AUTOMATED QUANTIFICATION, COMPUTED-TOMOGRAPHY, I-123 IODOBENZAMIDE, NEUROLEPTICS, European Union, Female, Humans, Male, Positron-Emission Tomography, Practice Guidelines as Topic, Radiopharmaceuticals, Receptors, Dopamine D2, Synaptic Transmission, Tomography, Emission-Computed, Single-Photon, 0299 Other Physical Sciences, 1103 Clinical Sciences, Nuclear Medicine & Medical Imaging

Abstract:

The guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The aims of the guidelines are to assist nuclear medicine practitioners in making recommendations, performing, interpreting and reporting the results of clinical dopamine D2 receptor SPECT or PET studies, and to achieve a high quality standard of dopamine D2 receptor imaging, which will increase the impact of this technique in neurological practice.The present document is an update of the first guidelines for SPECT using D2 receptor ligands labelled with (123)I [1] and was guided by the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines intend to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.